New immunotherapy targets rare cancers by harnessing the Body's immune system
NCT ID NCT07686367
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new drug called brenetafusp (IMC-F106C) in people with rare cancers—synovial sarcoma and myxoid liposarcoma—that have spread or cannot be surgically removed. The drug is a type of immunotherapy designed to guide the body's immune cells to attack cancer cells that carry a specific marker called PRAME. The study aims to see if the drug can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brenetafusp (IMC-F106C), an immune-mobilizing T-cell receptor drug
- What this could lead to
- If successful, this could offer a new treatment option for people with rare, hard-to-treat cancers that have spread or cannot be removed by surgery.
- What could go wrong
- This is an early-phase trial with a small number of participants. The drug may not shrink tumors or improve survival, and it could cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MYXOID LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat cancers
- Engineered immune cells take aim at multiple cancers in early trial
- Designer immune cells take on rare sarcomas
- Supercharged immune cells take on Hard-to-Treat cancers
- Engineered immune cells take on rare sarcomas in new trial
- New combo therapy shows promise for rare liposarcoma